ObsEva SA, en liquidation is a Switzerland-based company which provides services in the fields of research, development, manufacture, registration, promotion and marketing of biotechnical and pharmaceutical products.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
07/08/26	$0.000100	+9,900.00%	42,067
04/08/26	$0.000001	-99.00%	225

Delayed Quote OTC Markets

More quotes

Market Closed - OTC Markets Other stock markets 23:45:10 07/08/2026 +04			5-day change	1st Jan Change
0.000100 ^USD	+9,900.00%		0.00%	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT

Market Cap	4.1M 3.55M 3.31M 3.04M 5.72M 390M 5.81M 38.87M 15.26M 196M 15.4M 15.06M 647M	P/E 2021	-2.57x	P/E 2022	-0.45x
Enterprise Value	-1.3M -1.12M -1.05M -960K -1.81M -123M -1.83M -12.28M -4.82M -61.81M -4.87M -4.76M -204M	EV / Sales 2021	-	EV / Sales 2022	0.65x
Free-Float	70.16%	Yield 2021 *	-	Yield 2022	-

20/04/23	ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq	MT
20/04/23	ObsEva to Change Central Securities Depositary to SIX SIS; Shares Up 9%	MT
12/04/23	Insider Buy: Obseva	MT
06/04/23	ObsEva SA announced that it has received CHF 0.344 million in funding	CI
01/04/23	ObsEva SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
31/03/23	ObsEva SA Auditor Raises 'Going Concern' Doubt	CI
22/03/23	ObsEva SA(OTCPK:OBSV.F) dropped from NASDAQ Composite Index	CI
15/03/23	ObsEva to Delist from Nasdaq, Deregister from US SEC	MT
13/03/23	ObsEva Names New CEO From May, Appoints Interim Chairman	MT
13/03/23	ObsEva Names New Interim Chairman, CEO as Reorganization Continues	MT
13/03/23	ObsEva SA Announces CEO Changes, Effective on or About May 1, 2023	CI
13/03/23	ObsEva SA Announces Executive Changes	CI
03/03/23	Top Premarket Gainers	MT

30/08/22	HC Wainwright Downgrades ObsEva to Neutral from Buy	MT
01/08/22	Canaccord Genuity Downgrades ObsEva to Hold From Buy, Adjusts Price Target to $1 From $12	MT
29/07/22	Cantor Fitzgerald Cuts ObsEva to Neutral From Overweight, Price Target to $1 From $6	MT
03/06/22	Cantor Fitzgerald Starts ObsEva at Overweight With $6 Price Target	MT
26/04/22	Canaccord Genuity Starts ObsEva at Buy With $12 Price Target	MT

ObsEva SA Stock

Stocks

OBSEF

CH1260041939

Biotechnology & Medical Research

Valuation: ObsEva SA

Chart: ObsEva SA

Latest news : ObsEva SA

Analysts' recommendations: ObsEva SA

Press Releases: ObsEva SA

News in other languages: ObsEva SA

Quotes and Performance

Course Extremes

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
20/04/23	ObsEva Announces Change of Central Securities Depositary	GL
01/04/23	ObsEva Files Year End 2022 Financial Statements	GL
23/03/23	OBSEVA SA : Other Events (form 8-K)	AQ
15/03/23	ObsEva : Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange - Form 8-K	PU

20/04/23	Obseva-Aktien erhalten im Zuge von Nasdaq-Dekotierung neue ISIN-Nummer
06/04/23	Bourse Zurich: le SMI maintient ses gains à l'approche de la mi-journée
06/04/23	Bourse Zurich: ouverture en hausse avant le long week-end pascal
01/04/23	Obseva bleibt 2022 tief in den roten Zahlen
01/04/23	Obseva reste profondément en rouge en 2022, doutes sur la suite

1 week	0		0
1 month	0		0
Current year	0		0
1 year	0		0.05
3 years	0		0.4
5 years	0		3.35
10 years	0		20.35

Date	Insider	Type	Main position	Quantity	% Market Cap.
06/04/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
28/02/23	Ernest Loumaye	Buy	Chief Executive Officer	4,000,000	3.7138%
23/02/23	William Brown	Free	Chief Executive Officer	250,000	0.2321%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
OBSEVA SA	+9,900.00%	0.00%	0.00%	-99.75%	11.72K
WUXI APPTEC CO., LTD.	+8.49%	+20.55%	+70.77%	+110.32%	68.12B
ARGENX SE	+1.25%	+2.44%	+34.27%	+70.43%	55.18B
INSMED INCORPORATED	-1.09%	+32.96%	+19.67%	+494.56%	28.63B
WUXI BIOLOGICS (CAYMAN) INC.	+10.83%	+18.38%	+56.20%	+6.03%	23.99B
BIONTECH SE	+2.72%	+3.41%	-16.11%	-7.96%	23.53B
GENMAB A/S	+6.50%	+7.56%	+44.65%	-21.73%	18.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+6.20%	+11.51%	+33.87%	+693.38%	16.44B
PHARMAESSENTIA CORPORATION	-3.88%	+16.98%	+199.30%	+359.77%	15.83B
EXELIXIS, INC.	+3.58%	+1.96%	+43.35%	+163.76%	13.4B
Average	+993.46%	+10.51%	+48.60%	+176.88%	26.36B
Weighted average by Cap.	+4.36%	+13.10%	+50.69%	+168.47%

	2021	2022
Net sales	-	19.64M 16.99M 15.86M 14.55M 27.37M 1.87B 27.8M 186M 73.05M 937M 73.74M 72.13M 3.1B
Net income	-58.38M -50.5M -47.16M -43.26M -81.36M -5.56B -82.66M -553M -217M -2.78B -219M -214M -9.21B	-29.88M -25.85M -24.14M -22.14M -41.64M -2.84B -42.31M -283M -111M -1.43B -112M -110M -4.71B
Net Debt	-28.08M -24.28M -22.68M -20.8M -39.13M -2.67B -39.75M -266M -104M -1.34B -105M -103M -4.43B	-5.4M -4.67M -4.36M -4M -7.52M -514M -7.64M -51.15M -20.08M -257M -20.27M -19.82M -851M